PCBD2

Across TCGA pan-cancer cohorts, PCBD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCBD2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PCBD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCBD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PCBD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.883	0.983	.003	34	view →
LUAD	DFS	Quartile	III,IV	0.373	0.917	.007	28	view →
CCRCC	DFS	Tertile	All	0.978	0.421	.001	20	view →
PDAC	OS	Median	II,III,IV	0.608	0.398	.024	10	view →
GBM	OS	Median	All	0.641	0.431	.023	3	view →
UCEC	OS	Quartile	All	1.000	0.862	.038	2	view →
LSCC	OS	Tertile	All	0.670	0.866	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCBD2–HNSC (DFS)

Open the HNSC breakdown →